Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
BioMarin Pharmaceutical Stock Quote

BioMarin Pharmaceutical (NASDAQ: BMRN)

Price as of July 18, 2024, 4:00 p.m. ET

BioMarin Pharmaceutical Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
BMRN -4.29% +2.17% +0.43% +545%
S&P +22.68% +87.74% +13.43% +309%

BioMarin Pharmaceutical Company Info

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

News & Analysis

The Fool has written over 200 articles on BioMarin Pharmaceutical.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.